Jade Biosciences, Inc., a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer (CMO), effective today.
Dr. Conner is an accomplished biopharmaceutical executive with extensive experience spanning clinical development, translational medicine, regulatory strategy and mechanism-based drug development, across early- to late-stage programs. As Chief Medical Officer, he will lead Jade’s clinical and medical organization, overseeing development strategy and data generation to support the advancement of the Company’s differentiated pipeline of potentially disease-modifying therapies for autoimmune diseases.
